CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

How attractive is the healthcare sector for investors now?

By David Burrows

11:12, 20 January 2022

GSK head office in Middlesex, UK – Photo: Alamy
GSK head office in Middlesex in the UK – Photo: Alamy

This week saw major stock movements in some of the biggest names in the healthcare industry as a bidding affair unfolded between two consumer healthcare majors – GSK and Unilever. 

There might have been some quick gains for those trading on the back of this potential acquisition, but for investors looking at the broader sector what is there to whet their risk appetite right now? 

Capital.com probes analysts to see if there are any good opportunities to invest in the sector or are the valuations somewhat stretched?  

GSK turns down Unilever’s bid

On Monday, GSK’s stock price went up 4.55% in early morning trade to 1,715.63p while Unilever’s stock price was down 6.86% to 3,666.50p. The moves were an immediate reaction to the news that GSK had turned down a £50bn bid from Unilever for the GSK-Pfizer consumer business.

Yesterday, Unilever released a statement that it would not increase its offer above £50bn and insisted it would not change its view on the firm’s fundamental value.

The Unilever stock price rose slightly since then to around the 3,720p mark, perhaps reflecting some analysts’ views that Unilever’s valuation of the business was already at the top end and also over concerns on how the acquisition would be financed.  

On the flip side, GSK’s stock price fell following Unilever’s announcement – down to the 1,635p mark mid-morning today.

What is your sentiment on UK100?

8406.6
Bullish
or
Bearish
Vote to see Traders sentiment!

Hidden gems in a huge sector

Back in the spotlight, and given the size of the healthcare sector and the variety of companies in it, it is hard to imagine a time when investors couldn’t find a few gems.  

As James Cooke, director of investment and head of global equities at Ashburton Investments explains: “Healthcare spans a number of areas from the conservative relative low volatility to high-risk biotech. While there are some areas of overvaluation, in particular, we believe that in the diagnostics space, there are certainly good opportunities.”

AstraZeneca, who notably produced their Covid vaccine on a not-for-profit basis during the pandemic, for example, remains a favoured stock in the Ashburton Global Leaders Equity Fund.

“The company offers one of the highest de-risked growth prospects of mega capitalisation pharmaceutical companies, with a young portfolio of approved products likely to be approved in other clinical settings,” says Cooke.

“Within the medical devices space, Smith & Nephew stands out as a company on a steep discount to peers and looks set to benefit from a return of elective procedures. Hip and knee operations have been deferred rather than cancelled and there is substantial pent up deferred demand,” adds Cooke.

He believes that while mergers and acquisitions within orthopaedics would not be possible given high industry concentration, the company would make a good acquisition for a large medical devices company looking to enter the space.

Dr Gareth Blades, an analyst at Amati Global Investors, picks out two pharma names – US company Indivior and UK-based Amryt.

Amryt Pharma’s Filsuvez is seeking approval from the Food and Drug Administration in February this year for Filsuvez is a topical gel that can be applied at home by dystrophic epidermolysis bullosa (EB) sufferers. It claims to significantly increase the speed of wound healing in cases of EB.  

Dr Blades believes approval would provide an additional boost to a business that he says had already impressed after a challenging period.

HK50

19,562.80 Price
-0.830% 1D Chg, %
Long position overnight fee -0.0225%
Short position overnight fee 0.0005%
Overnight fee time 21:00 (UTC)
Spread 30.0

US30

39,809.60 Price
-0.460% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 2.2

US500

5,310.00 Price
+0.090% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.7

US100

18,661.20 Price
+0.610% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

Dr Blades adds that Amryt had something of a chequered history as the merger with a US company Chiasma was a complicated transaction. But he said that the firm has now gone through the process of taking out all the excess costs.

“…for instance moving operations out of Boston which was very expensive. They have a highly effective sales model in place now and have had three or more upgrades to full-year numbers.”   

Some turnaround stories

Indivior is a different story – but another example of a turnaround. As Dr Blades explains, in 2020, the company hit a low point when it was fined and its then chief executive Shaun Thaxter pleaded guilty to FDA charges of misbranding its opioid drug Suboxone.  

Suboxone was a drug product approved for use by recovering opioid addicts to avoid or reduce withdrawal symptoms while they undergo treatment.

“The Indivior CEO was fired and the company then had to show its internal processes were watertight. It is probably the most heavily audited company in the sector now. It has seen steady growth in sales and its drug, Sublocade is very successful and could easily become a billion-dollar drug. There is currently no competitor in the market to it.”

Sublocade is used to treat adults with moderate to severe addiction (dependence) to opioid drugs.

Moritz Sitte, co-manager of the Baillie Gifford European Growth Trust, recently bought a stake in Dassault Systemes.

“Over more than forty years, Dassault has built an enviable reputation amongst its customers as a leading provider of 3D project management software. It started out in serving the aerospace and auto industries, and is now trying to achieve similar success with customers in the healthcare sector,” said Sitte.

“Dassault is digitising this huge industry by introducing software to run clinical trials much faster than in the past; 60% of covid vaccine trials were run using Dassault’s Medidata software platform,” added Sitte.

Impact of Covid

Tackling waiting lists is an ongoing challenge not just in the UK but globally, which has been exacerbated by the Covid-19 pandemic.

Dr Blades explains that one obvious way to tackle lists quickly was by improved diagnostic and screening tests. Renalytix, a company favoured by Dr Blade, identifies the risk of diabetes. “… (it) had a high rating but has come off a lot. Over 18 months to two years, that company is capable of significant cash generation,” he said.

In terms of valuations he says there has been something of a sell-off – notably amongst some of the earlier-stage businesses.

“These businesses continued to operate during the pandemic but didn’t have the sales reps out on the road selling,” adds Dr Blade. But, as lockdowns are phased out, this situation changes and companies such as Renalytix are well placed.

“They have built up sales rep numbers, invested in IT and have all they need to drive revenue growth. Significantly, they will be able to get into hospitals now too. Once again, this is a company that has very little competition in its market.”  

Markets in this article

AZNl
AstraZeneca - GBP
121.11 USD
0.16 +0.130%
DSY
Dassault System
37.93 USD
0.21 +0.560%
GSKl
GSK
17.780 USD
-0.095 -0.540%
INDV
Indivior
13.3915 USD
-0.1495 -1.110%
ULVR
Unilever - GBP
43.665 USD
-0.33 -0.770%

Rate this article

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided in this article is for information purposes only and should not be understood as investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents and has not been prepared in accordance with the legal requirements designed to promote investment research independence. While the information in this communication, or on which this communication is based, has been obtained from sources that Capital.com believes to be reliable and accurate, it has not undergone independent verification. No representation or warranty, whether expressed or implied, is made as to the accuracy or completeness of any information obtained from third parties. If you rely on the information on this page, then you do so entirely at your own risk.

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading